Rezolute's Stock Plummets 87.2% Following Phase 3 Trial Failure
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 30 2025
0mins
Should l Buy RZLT?
Source: Globenewswire
- Clinical Trial Results Disappoint: Rezolute's Phase 3 sunRIZE study evaluating ersodetug failed to meet its primary endpoint, with a 45% reduction in hypoglycemia events at the highest dose showing no statistical significance compared to the placebo group's 40% improvement, indicating insufficient drug efficacy.
- Stock Price Plummets: Following the trial results announcement, Rezolute's stock price fell by $9.44, or 87.2%, closing at $1.77 per share on December 19, 2025, reflecting extreme market pessimism regarding the company's future prospects.
- Legal Investigation Initiated: Pomerantz LLP is investigating whether Rezolute engaged in securities fraud or other unlawful business practices, which could negatively impact the reputation of the company's management and its future operations.
- Investor Reaction Strong: The failure to meet key trial endpoints has severely shaken investor confidence in Rezolute, potentially leading to reduced financing and partnership opportunities, thereby affecting the company's long-term strategic development.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RZLT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RZLT
Wall Street analysts forecast RZLT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RZLT is 6.29 USD with a low forecast of 2.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Analyst Rating
5 Buy
4 Hold
0 Sell
Moderate Buy
Current: 3.120
Low
2.00
Averages
6.29
High
20.00
Current: 3.120
Low
2.00
Averages
6.29
High
20.00
About RZLT
Rezolute, Inc. is a late-stage rare disease company, which is focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (HI). Its lead clinical asset, Ersodetug (formerly RZ358), is a potential treatment for hypoglycemia caused by multiple forms of hyperinsulinism including congenital HI and tumor HI. Ersodetug is an intravenously administered human monoclonal antibody that binds to a unique site (allosteric) on the insulin receptor in insulin target tissues, such as in the liver, fat, and muscle. Congenital is a rare pediatric genetic disorder characterized by excessive production of insulin by the pancreas. RZ402, which is an oral plasma kallikrein inhibitor (PKI) being developed as a potential therapy for the chronic treatment of diabetic macular edema (DME). DME is a vascular complication of diabetes and a leading cause of blindness. RZ402 is designed to block bradykinin production and its resulting effects on vascular leakage and inflammation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Faruqi & Faruqi Investigates Losses in Rezolute Stock
- Stock Price Plunge: Rezolute, Inc. shares plummeted on December 11, 2025, due to disappointing results from its Phase 3 sunRIZE clinical trial, collapsing from approximately $10.94 to $0.90, reflecting an 85-90% drop and investor disillusionment with the company's prospects.
- Legal Investigation Launched: Faruq & Faruqi LLP is investigating potential claims against Rezolute, urging investors who suffered significant losses to contact partner Josh Wilson directly, indicating the firm's commitment to protecting investor rights.
- Clinical Trial Failure: The lead drug candidate ersodetug failed to meet both primary and key secondary endpoints in clinical trials, leading to a significant decline in market confidence and the potential for increased legal actions against the company.
- Investor Rights Protection: Since its founding in 1995, Faruqi & Faruqi has recovered hundreds of millions for investors, showcasing its expertise in securities law and aiming to provide legal support for affected investors.
See More
Faruqi & Faruqi Investigates Rezolute Losses
- Legal Investigation Launched: Faruq & Faruqi LLP is investigating potential claims against Rezolute, Inc. after its stock plummeted on December 11, 2025, due to disappointing clinical trial results, leading to significant investor losses.
- Clinical Trial Failure: The Phase 3 sunRIZE clinical trial for Rezolute's lead drug candidate, ersodetug, failed to meet both primary and key secondary endpoints, severely impacting the drug's market prospects and investor confidence.
- Significant Investor Losses: As the trial results did not show statistical significance, Rezolute's stock price sharply declined, potentially resulting in millions of dollars in losses for investors, prompting Faruqi & Faruqi to encourage affected investors to discuss their legal options.
- Law Firm Background: Founded in 1995, Faruqi & Faruqi has recovered hundreds of millions for investors and has offices in New York, Pennsylvania, California, and Georgia, committed to protecting investor rights.
See More
Faruqi & Faruqi Investigates Investor Losses in Rezolute
- Legal Investigation Launched: Faruq & Faruqi LLP is investigating potential claims against Rezolute, Inc., aiming to provide legal support for investors who have suffered significant losses, highlighting the legal risks the company may face.
- Investor Rights Advocacy: The firm encourages investors who have incurred losses in Rezolute stock or options to contact partner Josh Wilson directly, demonstrating its commitment to protecting investor rights and actively advocating for their interests.
- Historical Performance Review: Since its founding in 1995, Faruqi & Faruqi has recovered hundreds of millions of dollars for investors, showcasing its strong capabilities and extensive experience in securities law, which enhances investor trust in its services.
- Contact Information Provided: Investors can reach out to Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310), offering a convenient communication channel for affected investors seeking legal assistance.
See More
Faruqi & Faruqi Encourages Rezolute Investors to Discuss Legal Options
- Legal Consultation Advocacy: Faruq & Faruqi's Securities Litigation Partner Josh Wilson encourages investors who have suffered significant losses in Rezolute stock or options to contact him directly, highlighting the firm's commitment to investor rights.
- Potential Claims Investigation: The firm is investigating potential claims against Rezolute, Inc., indicating that the company may face legal risks, which investors should monitor to protect their interests.
- Investor Loss Focus: Faruq & Faruqi emphasizes that investors who have incurred significant losses in Rezolute should seek legal advice promptly, reflecting a proactive approach to investor protection and potential compensation.
- Firm Background Overview: Since its founding in 1995, Faruq & Faruqi has recovered hundreds of millions of dollars for investors, showcasing its expertise and successful track record in securities law, thereby enhancing investor trust in its services.
See More
Faruqi & Faruqi Investigates Rezolute Loss Claims After Disappointing Trial Results
- Legal Investigation Launched: Faruq & Faruqi LLP is investigating potential claims against Rezolute, Inc. following a significant stock price drop on December 11, 2025, due to disappointing clinical trial results.
- Clinical Trial Failure: Rezolute's Phase 3 sunRIZE trial failed to meet both primary and key secondary endpoints, with the highest dose showing no statistically significant reduction in hypoglycemia events, undermining investor confidence.
- Investor Losses: The poor trial results have led to substantial losses for investors in Rezolute, prompting Faruqi & Faruqi to encourage affected investors to reach out directly to discuss their legal options.
- Law Firm Background: Since its founding in 1995, Faruqi & Faruqi has recovered hundreds of millions of dollars for investors, demonstrating its strong capabilities and experience in the securities law sector.
See More
Rezolute, Inc. Under Investigation for Securities Fraud as Stock Plummets 87.2%
- Securities Fraud Investigation: Pomerantz LLP is investigating whether Rezolute, Inc. has engaged in securities fraud or other unlawful business practices, advising investors to contact their attorney for more information.
- Poor Clinical Trial Results: On December 11, 2025, Rezolute announced that its sunRIZE study did not meet its primary endpoint for treating congenital hyperinsulinism with ersodetug, showing only a 45% reduction in hypoglycemia events at the highest dose, which was not statistically significant compared to the placebo group.
- Stock Price Collapse: Following the disappointing clinical trial results, Rezolute's stock plummeted 87.2% on December 19, 2025, falling $9.44 to close at $1.77 per share, indicating extreme market pessimism regarding the company's future prospects.
- Potential Legal Consequences: The ongoing investigation may lead to class action lawsuits against Rezolute, potentially exacerbating investor losses and impacting the company's future financing capabilities and market trust.
See More
Faruqi & Faruqi Investigates Losses in Rezolute Stock
- Stock Price Plunge: Rezolute, Inc. shares plummeted on December 11, 2025, due to disappointing results from its Phase 3 sunRIZE clinical trial, collapsing from approximately $10.94 to $0.90, reflecting an 85-90% drop and investor disillusionment with the company's prospects.
- Legal Investigation Launched: Faruq & Faruqi LLP is investigating potential claims against Rezolute, urging investors who suffered significant losses to contact partner Josh Wilson directly, indicating the firm's commitment to protecting investor rights.
- Clinical Trial Failure: The lead drug candidate ersodetug failed to meet both primary and key secondary endpoints in clinical trials, leading to a significant decline in market confidence and the potential for increased legal actions against the company.
- Investor Rights Protection: Since its founding in 1995, Faruqi & Faruqi has recovered hundreds of millions for investors, showcasing its expertise in securities law and aiming to provide legal support for affected investors.
See More
Faruqi & Faruqi Investigates Rezolute Losses
- Legal Investigation Launched: Faruq & Faruqi LLP is investigating potential claims against Rezolute, Inc. after its stock plummeted on December 11, 2025, due to disappointing clinical trial results, leading to significant investor losses.
- Clinical Trial Failure: The Phase 3 sunRIZE clinical trial for Rezolute's lead drug candidate, ersodetug, failed to meet both primary and key secondary endpoints, severely impacting the drug's market prospects and investor confidence.
- Significant Investor Losses: As the trial results did not show statistical significance, Rezolute's stock price sharply declined, potentially resulting in millions of dollars in losses for investors, prompting Faruqi & Faruqi to encourage affected investors to discuss their legal options.
- Law Firm Background: Founded in 1995, Faruqi & Faruqi has recovered hundreds of millions for investors and has offices in New York, Pennsylvania, California, and Georgia, committed to protecting investor rights.
See More
Faruqi & Faruqi Investigates Investor Losses in Rezolute
- Legal Investigation Launched: Faruq & Faruqi LLP is investigating potential claims against Rezolute, Inc., aiming to provide legal support for investors who have suffered significant losses, highlighting the legal risks the company may face.
- Investor Rights Advocacy: The firm encourages investors who have incurred losses in Rezolute stock or options to contact partner Josh Wilson directly, demonstrating its commitment to protecting investor rights and actively advocating for their interests.
- Historical Performance Review: Since its founding in 1995, Faruqi & Faruqi has recovered hundreds of millions of dollars for investors, showcasing its strong capabilities and extensive experience in securities law, which enhances investor trust in its services.
- Contact Information Provided: Investors can reach out to Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310), offering a convenient communication channel for affected investors seeking legal assistance.
See More
Faruqi & Faruqi Encourages Rezolute Investors to Discuss Legal Options
- Legal Consultation Advocacy: Faruq & Faruqi's Securities Litigation Partner Josh Wilson encourages investors who have suffered significant losses in Rezolute stock or options to contact him directly, highlighting the firm's commitment to investor rights.
- Potential Claims Investigation: The firm is investigating potential claims against Rezolute, Inc., indicating that the company may face legal risks, which investors should monitor to protect their interests.
- Investor Loss Focus: Faruq & Faruqi emphasizes that investors who have incurred significant losses in Rezolute should seek legal advice promptly, reflecting a proactive approach to investor protection and potential compensation.
- Firm Background Overview: Since its founding in 1995, Faruq & Faruqi has recovered hundreds of millions of dollars for investors, showcasing its expertise and successful track record in securities law, thereby enhancing investor trust in its services.
See More
Faruqi & Faruqi Investigates Rezolute Loss Claims After Disappointing Trial Results
- Legal Investigation Launched: Faruq & Faruqi LLP is investigating potential claims against Rezolute, Inc. following a significant stock price drop on December 11, 2025, due to disappointing clinical trial results.
- Clinical Trial Failure: Rezolute's Phase 3 sunRIZE trial failed to meet both primary and key secondary endpoints, with the highest dose showing no statistically significant reduction in hypoglycemia events, undermining investor confidence.
- Investor Losses: The poor trial results have led to substantial losses for investors in Rezolute, prompting Faruqi & Faruqi to encourage affected investors to reach out directly to discuss their legal options.
- Law Firm Background: Since its founding in 1995, Faruqi & Faruqi has recovered hundreds of millions of dollars for investors, demonstrating its strong capabilities and experience in the securities law sector.
See More
Rezolute, Inc. Under Investigation for Securities Fraud as Stock Plummets 87.2%
- Securities Fraud Investigation: Pomerantz LLP is investigating whether Rezolute, Inc. has engaged in securities fraud or other unlawful business practices, advising investors to contact their attorney for more information.
- Poor Clinical Trial Results: On December 11, 2025, Rezolute announced that its sunRIZE study did not meet its primary endpoint for treating congenital hyperinsulinism with ersodetug, showing only a 45% reduction in hypoglycemia events at the highest dose, which was not statistically significant compared to the placebo group.
- Stock Price Collapse: Following the disappointing clinical trial results, Rezolute's stock plummeted 87.2% on December 19, 2025, falling $9.44 to close at $1.77 per share, indicating extreme market pessimism regarding the company's future prospects.
- Potential Legal Consequences: The ongoing investigation may lead to class action lawsuits against Rezolute, potentially exacerbating investor losses and impacting the company's future financing capabilities and market trust.
See More
